Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. November 2025 07:00 ET | Quelle: Pasithea

Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data

-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin...
02. Juni 2025 08:02 ET | Quelle: Pasithea

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

PAS-004 shows early signs of efficacy and strong tolerability in Phase 1 cancer trial, with tumor reductions and disease stability in pre-treated patients
24. April 2025 07:02 ET | Quelle: Pasithea

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Tx (Nasdaq: KTTA) will present updated Phase 1 data for MEK inhibitor PAS-004 in MAPK-driven cancers at ASCO 2025 on June 2 in Chicago.
10. April 2025 07:02 ET | Quelle: Pasithea

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea’s PAS-004 cancer trial clears safety review; no DLTs or rash seen, advancing to 30mg dose in Phase 1 for MAPK-driven tumors.
26. September 2024 07:02 ET | Quelle: Pasithea

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics' PAS-004 shows positive Phase 1 data: well-tolerated, no toxicities, promising efficacy in NF1 and MAPK-driven cancers.